Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 17, Issue 9, Pages 1073-1080Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.2013.819853
Keywords
cancer; drug resistance; microRNA; miR-21
Categories
Funding
- National Natural Scientific Foundation of China [81100714, 81171923]
- Foundation of Shaanxi Province Science and Technology research [2012KJXX-20]
- Xijing Zhutui Project [12Z03]
- Top Ph.D. Foundation of China [201075]
Ask authors/readers for more resources
Introduction: Drug resistance is a major clinical obstacle to the successful treatment of human cancer. The microRNAs-21 (miR-21), an oncomiR, may play an important role in the progress of drug resistance. Areas covered: This review covers all related literature on miR-21 in drug resistance of human cancers and analyzes the expression, biological functions and targets of it. This study also envisages future developments toward its clinical and therapeutic applications in cancer treatment. Expert opinion: The miR-21 may promote the drug resistance of various cancers. Inhibitors of miR-21 may function as effective approaches for reversing drug resistance in cancer cells. There is a tough way from discovering the function of miR-21 to clinical use. Further understanding of miR-21-mediated signaling pathways will help to promote the therapeutic-clinical use of miR-21 in cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available